Avid Bioservices, Inc. (CDMO): Price and Financial Metrics


Avid Bioservices, Inc. (CDMO): $22.03

0.65 (+3.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CDMO POWR Grades


  • CDMO scores best on the Growth dimension, with a Growth rank ahead of 74.61% of US stocks.
  • CDMO's strongest trending metric is Stability; it's been moving down over the last 48 weeks.
  • CDMO ranks lowest in Value; there it ranks in the 7th percentile.

CDMO Stock Summary

  • CDMO's current price/earnings ratio is 233.69, which is higher than 97.17% of US stocks with positive earnings.
  • With a year-over-year growth in debt of 640.69%, Avid Bioservices Inc's debt growth rate surpasses 98.02% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Avid Bioservices Inc is reporting a growth rate of -669.71%; that's higher than just 3.18% of US stocks.
  • Stocks that are quantitatively similar to CDMO, based on their financial statements, market capitalization, and price volatility, are PNTG, ONEM, PLAG, CHCI, and WNS.
  • CDMO's SEC filings can be seen here. And to visit Avid Bioservices Inc's official web site, go to avidbio.com.

CDMO Valuation Summary

  • CDMO's price/sales ratio is 15.4; this is 305.26% higher than that of the median Healthcare stock.
  • Over the past 243 months, CDMO's EV/EBIT ratio has gone up 130.4.
  • Over the past 243 months, CDMO's price/earnings ratio has gone up 461.6.

Below are key valuation metrics over time for CDMO.

Stock Date P/S P/B P/E EV/EBIT
CDMO 2021-08-31 15.4 19.1 446.4 115.5
CDMO 2021-08-30 15.4 19.0 445.6 115.3
CDMO 2021-08-27 15.4 19.0 444.9 115.1
CDMO 2021-08-26 15.3 18.8 441.0 114.0
CDMO 2021-08-25 15.8 19.5 457.4 118.4
CDMO 2021-08-24 15.4 18.9 443.8 114.8

CDMO Growth Metrics

  • The 5 year net cashflow from operations growth rate now stands at 115.16%.
  • The 4 year cash and equivalents growth rate now stands at -40.96%.
  • The 3 year cash and equivalents growth rate now stands at -45.98%.
CDMO's revenue has moved up $43,600,000 over the prior 52 months.

The table below shows CDMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 101.23 26.513 5.612
2021-03-31 95.868 31.182 3.318
2020-12-31 80.812 16.369 -0.955
2020-09-30 72.591 10.544 -5.266
2020-06-30 69.84 6.022 -7.98
2020-03-31 59.702 5.827 -15.152

CDMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDMO has a Quality Grade of C, ranking ahead of 30.04% of graded US stocks.
  • CDMO's asset turnover comes in at 0.495 -- ranking 87th of 677 Pharmaceutical Products stocks.
  • ESPR, COCP, and ASLN are the stocks whose asset turnover ratios are most correlated with CDMO.

The table below shows CDMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-31 0.495 0.318 0.126
2021-04-30 0.587 0.306 0.157
2021-01-31 0.653 0.246 0.079
2020-10-31 0.672 0.199 0.002
2020-07-31 0.659 0.163 -0.044
2020-04-30 0.568 0.066 -0.173

CDMO Price Target

For more insight on analysts targets of CDMO, see our CDMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $28.25 Average Broker Recommendation 1.38 (Strong Buy)

CDMO Stock Price Chart Interactive Chart >

Price chart for CDMO

CDMO Price/Volume Stats

Current price $22.03 52-week high $28.36
Prev. close $21.38 52-week low $6.89
Day low $21.40 Volume 424,183
Day high $22.19 Avg. volume 640,832
50-day MA $24.08 Dividend yield N/A
200-day MA $19.94 Market Cap 1.35B

Avid Bioservices, Inc. (CDMO) Company Bio


Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate includes bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company was founded in 1981 and is based in Tustin, California.


CDMO Latest News Stream


Event/Time News Detail
Loading, please wait...

CDMO Latest Social Stream


Loading social stream, please wait...

View Full CDMO Social Stream

Latest CDMO News From Around the Web

Below are the latest news stories about Avid Bioservices Inc that investors may wish to consider to help them evaluate CDMO as an investment opportunity.

Dear SRNG Stock Fans, Mark Your Calendars for Ginkgo Bioworks’ Debut on Sept. 17

Soaring Eagle Acquisition is about to complete its merger with Ginkgo Bioworks, and SRNG stock is reacting well.

Samuel O'Brient on InvestorPlace | September 15, 2021

Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround

Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | September 14, 2021

Avid Bioservices, inc (CDMO) Q1 2021 Earnings Call Transcript

On today's call, we have Nick Green, President and CEO; and Dan Hart, Chief Financial Officer. Today, we'll be providing an overview of Avid Bioservices' contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended July 31, 2021.

Yahoo | September 9, 2021

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments

-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- -- Signed $23 Million in New Business Orders and Ended the Quarter with a Backlog of $110 Million -- -- Phase 1 and Phase 2 Expansion Efforts Advancing as Planned -- TUSTIN, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by prov

Yahoo | September 8, 2021

Avid Bioservices to Participate at Upcoming Investor Conferences

TUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that the company will participate in two upcoming investor conferences.

Intrado Digital Media | September 2, 2021

Read More 'CDMO' Stories Here

CDMO Price Returns

1-mo -8.59%
3-mo -12.23%
6-mo 30.74%
1-year 201.37%
3-year 213.82%
5-year 667.60%
YTD 90.90%
2020 50.46%
2019 87.07%
2018 5.67%
2017 78.80%
2016 -73.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 3.0573 seconds.